Sentynl acquires Eiger’s Zokinvy to treat rare genetic disease progeria
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 May 24
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 May 24
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 May 24
As per the pre-agreed terms of the JV, Bayer has secured full ownership of the entity which was…
03 May 24
Alkermes and Novo Nordisk also entered into subcontracting arrangements to continue certain development and manufacturing activities currently performed…
30 Apr 24
ONO will merge Deciphera with and into its fully owned subsidiary, with Deciphera as the surviving entity, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Apr 24
The binding offer consists of an upfront cash payment of €190m and up to €85m in potential earnout…
24 Apr 24
The deal includes EP262, a first-in-class, potent, highly selective, once-daily small molecule MRGPRX2 antagonist, and EP547, a first-in-class…
23 Apr 24
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
03 Apr 24
Under the deal, Genmab will gain global rights to ProfoundBio’s portfolio of next-generation ADCs which consists of three…
26 Mar 24
Cardior is engaged in the discovery and development of therapies that prevent, repair and reverse diseases of the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates